SpringWorks Therapeutics SWTX announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion recommending conditional ...

Merck KGaA has reached an agreement with SpringWorks on a $47-per-share takeover deal that values the US biotech at $3.9 billion. The acquisition – which was confirmed to be in the final stages ...

Hard on the heels of the disclosure that Merck KGaA is talking to SpringWorks about a possible takeover, a new FDA approval could have sweetened the deal. Stamford, Connecticut-based SpringWorks ...

The German pharmaceutical company Merck KGaA is negotiating the acquisition of the American manufacturer of drugs for the treatment of cancer and rare diseases SpringWorks Therapeutics Inc. This is ...

SpringWorks Therapeutics, a U.S.-based clinical-stage biopharmaceutical company, has been acquired by German pharmaceutical giant Merck KGaA in a $3.7 billion deal. Announced in early 2025, the ...

As soon as the news broke of a major layoff at New Haven biopharma company Arvinas earlier this month, texts and emails were flying across Connecticut between pharma executives, industry boosters and ...

SpringWorks Therapeutics (SWTX) gains EMA panel endorsement for Mirdametinib, a treatment for neurofibromatosis type 1. Read ...

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare ...

FILE- This May 1, 2018, file photo shows Merck corporate headquarters in Kenilworth, N.J. Pharmaceutical giant Merck will close its plant in Northumberland County, Pennsylvania. According to a ...

DURHAM, N.C.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today the opening of a new, $1 billion, 225,000-square-foot facility dedicated to ...

Randomized Phase III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small-Cell Lung Cancer (PREMER): A GICOR-GOECP-SEOR Study VOYAGER randomly assigned patients ...